TABLE 1.
Trial | Vector | Lot no. | PU/ml | PFU/ml | PU/PFUa | Doses used for each administration (PU) |
---|---|---|---|---|---|---|
Normal skin | AdGVCD.10 | 0061-0002 | 3.7 × 1011 | 1.0 × 1010 | 36 | 8 × 107–8 × 109 |
CF | AdGVCFTR.10 | 0056-0002 | 2.2 × 1011 | 3.7 × 1010 | 6 | 3 × 107–3 × 108.5 |
q3mo × 3 (part A) | ||||||
Individuals 1–8 | ||||||
AdGVCFTR.10 | 0045-007 | 1.4 × 1012 | 1.6 × 1011 | 9 | 3 × 109–3 × 1010 | |
Individuals 9–14 | ||||||
q15d × 4 (part B) | AdGVCFTR.10 | 0045-007 | 1.4 × 1012 | 1.6 × 1011 | 9 | 3 × 109.5 |
Metastatic colon cancer | AdGVCD.10 | 0061-0002 | 3.7 × 1011 | 1.0 × 1010 | 36 | 8 × 108–8 × 109 |
Coronary artery disease | AdGVVEGF121.10 | 0061-0003 | 4.0 × 1011 | 1.0 × 1010 | 40 | 4 × 108–4 × 109.5 |